- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Farmington Hills Today
By the People, for the People
Cantor Fitzgerald Initiates Coverage on Opus Genetics
Analysts set an 'overweight' rating and $15 price target on the biotech stock.
Mar. 30, 2026 at 12:08pm
Got story updates? Submit your updates here. ›
Cantor Fitzgerald began coverage on shares of Opus Genetics (NASDAQ:IRD), a clinical-stage ophthalmic biopharmaceutical company, in a research report issued on Monday. The firm set an 'overweight' rating and a $15.00 price target on the stock, indicating a potential upside of nearly 245% from the stock's current trading price.
Why it matters
This new analyst coverage from a respected firm like Cantor Fitzgerald could provide a boost to Opus Genetics' visibility and credibility among investors, potentially driving increased interest and investment in the stock. The bullish 'overweight' rating and lofty price target suggest the analysts see significant upside potential in the company's pipeline of treatments for refractive and retinal eye disorders.
The details
In addition to Cantor Fitzgerald's new coverage, several other analysts have also recently weighed in on Opus Genetics. B. Riley Financial started coverage on the stock in December with a 'buy' rating and $9 price target. Wall Street Zen upgraded the stock from 'sell' to 'hold' in March, while Craig Hallum set a $9 price target and 'buy' rating in the same month. Overall, the stock has an average 'Moderate Buy' rating from analysts, with a consensus price target of $9.90.
- Cantor Fitzgerald initiated coverage on Opus Genetics on March 30, 2026.
- B. Riley Financial started coverage on the stock on December 10th.
- Wall Street Zen upgraded Opus Genetics to 'hold' on March 1st.
- Craig Hallum set a $9 price target and 'buy' rating on March 11th.
The players
Cantor Fitzgerald
A global financial services firm that provides institutional equity and fixed income sales and trading, investment banking, and research services.
Opus Genetics
A clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.
The takeaway
The new analyst coverage from Cantor Fitzgerald, along with the firm's bullish outlook on Opus Genetics, could help drive increased investor interest and potentially boost the stock price if the company's pipeline continues to progress. However, investors should still conduct their own due diligence, as the stock has a 'Moderate Buy' rating overall and the $15 price target represents a significant premium to the current trading level.
